Thanner M, Nagel E
Institut für Medizinmanagement und Gesundheitswissenschaften, Universität Bayreuth, 95440, Bayreuth, Deutschland.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):843-8. doi: 10.1007/s00103-011-1300-7.
Advanced therapy medicinal products (ATMP) are associated with high expectations because they offer new opportunities for the treatment of diseases, e.g., the possibility of regenerating damaged or lost tissue. What the products (gene therapy, somatic cell therapy, and tissue engineered products) have in common is an innovative and complex development process that combines science and engineering. At the same time, this field of research is becoming increasingly interdisciplinary and requires international cooperation. A comprehensive assessment of ATMP has to take these issues into account. The application of Beauchamp and Childress' Four Principles (Principle-Based Ethics) as well as Discourse Ethics as a framework may lead to a broader consideration of medical ethics issues.
先进治疗医药产品(ATMP)寄予着人们很高的期望,因为它们为疾病治疗提供了新的机遇,例如具有使受损或缺失组织再生的可能性。这些产品(基因治疗、体细胞治疗和组织工程产品)的共同之处在于其创新且复杂的研发过程,该过程融合了科学与工程学。与此同时,这一研究领域正变得越来越具有跨学科性,并且需要国际合作。对先进治疗医药产品进行全面评估必须考虑到这些问题。将博尚和奇尔德雷斯的四项原则(基于原则的伦理)以及话语伦理学作为框架加以应用,可能会促使对医学伦理问题进行更广泛的考量。